MARIA DEL PILAR ESTEVEZ DIZ

(Fonte: Lattes)
Índice h a partir de 2011
21
Lattes
ORCID
Projetos de Pesquisa
Unidades Organizacionais
Instituto do Câncer do Estado de São Paulo, Hospital das Clínicas, Faculdade de Medicina - Médico
Instituto de Radiologia, Hospital das Clínicas, Faculdade de Medicina - Médico
LIM/24 - Laboratório de Oncologia Experimental, Hospital das Clínicas, Faculdade de Medicina

Filtros

Limpar filtros

Configurações

Indexador: WoS ×

Resultados de Busca

Agora exibindo 1 - 10 de 14
  • article 1 Citação(ões) na Scopus
    Applying mucosal barrier injury laboratory-confirmed bloodstream infection criteria in patients with solid tumors and hematologic malignancies: A retrospective cohort study looking for the real source of infection
    (2023) SILVA, Ana Carolina Puin da; VIEIRA, Michely Fernandes; FREIRE, Maristela Pinheiro; VAZ, Lumena; BONAZZI, Patricia Rodrigues; IBRAHIM, Karim Yaqub; DIZ, Maria Del Pilar Esteves; HOFF, Paulo Marcelo; PEREIRA, Juliana; ROCHA, Vanderson Geraldo; ABDALA, Edson
    We evaluated the interference of the mucosal barrier injury (MBI) laboratory-confirmed bloodstream infection (MBI-LCBI) criteria on the central-line-associated bloodstream infection (CLABSI) incidence density, and the proportion of catheter-related bloodstream infections (CRBSIs) among those classified as MBI. We detected 339 CLABSIs: 15.0% were classified as MBI-LCBIs, and among these, 19.6% were classified as CRBSIs.
  • conferenceObject
    Predictors of in-hospital mortality after unplanned admissions among adults with cancer aged 80 years and older
    (2022) NETO, F. Lazar; HIDALGO FILHO, C. M. T.; ROCHA, J. W. D.; SOBOTTKA, V. P.; STANGLER, L. T. B.; BENFATTI, G.; GUEDES, H.; CLARO, M. Z.; BONADIO, R. C.; DIZ, M. D. P. E.; HOFF, P. M.
  • article 0 Citação(ões) na Scopus
    A matched case-control study of the prognosis of early breast cancer in patients with Li-Fraumeni syndrome (BREAST TP53)
    (2023) PETRY, Vanessa; BONADIO, Renata Colombo; TESTA, Laura; COHN, Daniela JBH.; CAGNACCI, Allyne; CAMPOS, Roberta G.; FRAGOSO, Maria Candida Bv; ESTEVEZ-DIZ, Maria del Pilar
    Introduction: Breast cancer (BC) is the most common type of cancer in premenopausal women with germline TP53 pathogenic variants (mTP53) (Li Fraumeni syndrome -LFS). However, little is known about the BC prognosis in these patients. This study analyzed the BC-related oncologic outcomes of patients with LFS.Methods: We evaluated a cohort of LFS patients with BC in comparison with a control cohort of BC patients with no pathogenic variant in a hereditary cancer panel. The primary endpoint was recurrence-free survival (RFS). Due to the risk of second malignancies in LFS, only locoregional and distant recurrences were considered events for RFS. Secondary endpoints included rates of contralateral BC, overall survival (OS), and breast cancer-specific survival (BCSS).Results: Forty-one patients were evaluated in the mTP53 group and 82 in the control group. Median age at BC diagnosis was 40 and 41 years, respectively. The mTP53 group received less adjuvant radiotherapy than the control group (63.4% vs 93.9%, P < 0.001). Other relevant baseline characteristics and treatment received were similar between groups. 5y-RFS rates were 79.4% in the mTP53 versus 93.6% in the control group (HR 2.43, 95% CI 0.74-8.01, P = 0.143); and were not impacted by the use of adjuvant radiotherapy. 5y-BCSS rates were 92.2% and 98.6%, respectively (HR 1.87, IC95% 0.25-13.48, P = 0.534).Conclusions: Our results showed no statistically significant difference in BC-related RFS and BCSS between pa-tients with mTP53 and a control group with no pathogenic variant. Larger multicentric studies are warranted to confirm these results.
  • article 5 Citação(ões) na Scopus
    Multiple Criteria Decision Analysis (MCDA) for evaluating cancer treatments in hospitalbased health technology assessment: The Paraconsistent Value Framework
    (2022) CAMPOLINA, A. G.; ESTEVEZ-DIZ, M. Del Pilar; ABE, J. M.; SOáREZ, P. C. de
    Background In recent years, the potential of multi-criteria decision analysis (MCDA) in the health field has been discussed widely. However, most MCDA methodologies have given little attention to the aggregation of different stakeholder individual perspectives. Objective To illustrate how a paraconsistent theory-based MCDA reusable framework, designed to aid hospital-based Health Technology Assessment (HTA), could be used to aggregate individual expert perspectives when valuing cancer treatments. Methods An MCDA methodological process was adopted based on paraconsistent theory and following ISPOR recommended steps in conducting an MCDA study. A proof-of-concept exercise focusing on identifying and assessing the global value of first-line treatments for metastatic colorectal cancer (mCRC) was conducted to foster the development of the MCDA framework. Results On consultation with hospital-based HTA committee members, 11 perspectives were considered in an expert panel: medical oncology, oncologic surgery, radiotherapy, palliative care, pharmacist, health economist, epidemiologist, public health expert, health media expert, pharmaceutical industry, and patient advocate. The highest weights were assigned to the criteria ""overall survival""(mean 0.22), ""burden of disease""(mean 0.21) and ""adverse events""(mean 0.20), and the lowest weights were given to ""progression-free survival""and ""cost of treatment""(mean 0.18 for both). FOLFIRI and mFlox scored the highest global value score of 0.75, followed by mFOLFOX6 with a global value score of 0.71. mIFL was ranked last with a global value score of 0.62. The paraconsistent analysis (para-analysis) of 6 first-line treatments for mCRC indicated that FOLFIRI and mFlox were the appropriate options for reimbursement in the context of this study. Conclusion The Paraconsistent Value Framework is proposed as a step beyond the current MCDA practices, in order to improve means of dealing with individual expert perspectives in hospital- based HTA of cancer treatments. © 2022 Campolina et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
  • article 8 Citação(ões) na Scopus
    Pregnancy After Breast Cancer in Young BRCA Carriers
    (2024) LAMBERTINI, Matteo; BLONDEAUX, Eva; AGOSTINETTO, Elisa; HAMY, Anne-Sophie; KIM, Hee Jeong; MEGLIO, Antonio Di; MOLHO, Rinat Bernstein; HILBERS, Florentine; POGODA, Katarzyna; CARRASCO, Estela; PUNIE, Kevin; BAJPAI, Jyoti; IGNATIADIS, Michail; MOORE, Halle C. F.; PHILLIPS, Kelly-Anne; TOSS, Angela; ROUSSET-JABLONSKI, Christine; PECCATORI, Fedro A.; RENAUD, Tiphaine; FERRARI, Alberta; PALUCH-SHIMON, Shani; FRUSCIO, Robert; CUI, Wanda; WONG, Stephanie M.; VERNIERI, Claudio; RUDDY, Kathryn J.; DIECI, Maria Vittoria; MATIKAS, Alexios; ROZENBLIT, Mariya; VILLARREAL-GARZA, Cynthia; MARCHIS, Laura De; MASTRO, Lucia Del; PUGLISI, Fabio; ESTEVEZ-DIZ, Maria Del Pilar; RODRIGUEZ-WALLBERG, Kenny A.; MRINAKOVA, Bela; MEISTER, Sarah; LIVRAGHI, Luca; CLATOT, Florian; YERUSHALMI, Rinat; ANGELIS, Carmine De; SANCHEZ-BAYONA, Rodrigo; MEATTINI, Icro; CICHOWSKA-CWALINSKA, Natalia; BERLIERE, Martine; SALAMA, Mahmoud; GIORGI, Ugo De; SONNENBLICK, Amir; CHIODI, Camila; LEE, Young-Jin; MARIA, Camille; AZIM JR., Hatem A.; BONI, Luca; PARTRIDGE, Ann H.
    Importance Young women with breast cancer who have germline pathogenic variants in BRCA1 or BRCA2 face unique challenges regarding fertility. Previous studies demonstrating the feasibility and safety of pregnancy in breast cancer survivors included limited data regarding BRCA carriers.Objective To investigate cumulative incidence of pregnancy and disease-free survival in young women who are BRCA carriers.Design, Setting, and Participants International, multicenter, hospital-based, retrospective cohort study conducted at 78 participating centers worldwide. The study included female participants diagnosed with invasive breast cancer at age 40 years or younger between January 2000 and December 2020 carrying germline pathogenic variants in BRCA1 and/or BRCA2. Last delivery was October 7, 2022; last follow-up was February 20, 2023.Exposure Pregnancy after breast cancer.Main Outcomes and Measures Primary end points were cumulative incidence of pregnancy after breast cancer and disease-free survival. Secondary end points were breast cancer-specific survival, overall survival, pregnancy, and fetal and obstetric outcomes.Results Of 4732 BRCA carriers included, 659 had at least 1 pregnancy after breast cancer and 4073 did not. Median age at diagnosis in the overall cohort was 35 years (IQR, 31-38 years). Cumulative incidence of pregnancy at 10 years was 22% (95% CI, 21%-24%), with a median time from breast cancer diagnosis to conception of 3.5 years (IQR, 2.2-5.3 years). Among the 659 patients who had a pregnancy, 45 (6.9%) and 63 (9.7%) had an induced abortion or a miscarriage, respectively. Of the 517 patients (79.7%) with a completed pregnancy, 406 (91.0%) delivered at term (>= 37 weeks) and 54 (10.4%) had twins. Among the 470 infants born with known information on pregnancy complications, 4 (0.9%) had documented congenital anomalies. Median follow-up was 7.8 years (IQR, 4.5-12.6 years). No significant difference in disease-free survival was observed between patients with or without a pregnancy after breast cancer (adjusted hazard ratio, 0.99; 95% CI, 0.81-1.20). Patients who had a pregnancy had significantly better breast cancer-specific survival and overall survival.Conclusions and RelevanceIn this global study, 1 in 5 young BRCA carriers conceived within 10 years after breast cancer diagnosis. Pregnancy following breast cancer in BRCA carriers was not associated with decreased disease-free survival.
  • conferenceObject
    Frequency of radiotherapy-induced malignancies in Li-Fraumeni syndrome patients with early breast cancer and influence of the radiotherapy technique
    (2023) PETRY, V.; BONADIO, R. Colombo; MOUTINHO, K.; SENNA, L.; TESTA, L.; FRAGOSO, M. C.; DIZ, M. D. P. Estevez
  • conferenceObject
    DURVALUMAB, IN COMBINATION WITH AND FOLLOWING CHEMORADIOTHERAPY, IN LOCALLY ADVANCED CERVICAL CANCER: RESULTS FROM THE PHASE 3 INTERNATIONAL, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED CALLA TRIAL
    (2022) MONK, Bradley; TOITA, Takafumi; WU, Xiaohua; LIMON, Juan Carlos; ZHOU, Qi; TARNAWSKI, Rafal; MANDAI, Masaki; SHAPIRA-FROMMER, Ronnie; MAHANTSHETTY, Umesh; ESTEVEZ-DIZ, Maria Del Pilar; GODINEZ, Francisco Ramirez; VARGA, Szilvia; GALVEZ, Manuel Humberto Leiva; LEE, Jung-Yun; KREYNINA, Yulia; HOWELLS, Kathryn; WILDSMITH, Sophie; DRY, Hannah; NUNES, Ana; MAYADEV, Jyoti
  • article 0 Citação(ões) na Scopus
    Immune checkpoint inhibitors: here to stay
    (2023) CARVALHO, Filomena Marino; DIZ, Maria Del Pilar Estevez; CARVALHO, Jesus Paula
  • article 21 Citação(ões) na Scopus
    Mismatch Repair and Microsatellite Instability Testing for Immune Checkpoint Inhibitor Therapy: ASCO Endorsement of College of American Pathologists Guideline
    (2023) VIKAS, Praveen; MESSERSMITH, Hans; COMPTON, Carolyn; SHOLL, Lynette; BROADDUS, Russell R.; DAVIS, Anjee; ESTEVEZ-DIZ, Maria; GARJE, Rohan; KONSTANTINOPOULOS, Panagiotis A.; LEISER, Aliza; MILLS, Anne M.; NORQUIST, Barbara; OVERMAN, Michael J.; SOHAL, Davendra; TURKINGTON, Richard C.; JOHNSON, Tyler
    PURPOSE The College of American Pathologists (CAP) has developed a guideline on testing for mismatch repair (MMR) and microsatellite instability (MSI) for patients considered for immune checkpoint inhibitor therapy. ASCO has a policy and set of procedures for endorsing clinical practice guidelines that have been developed by other professional organizations.METHODS The CAP guideline was reviewed for developmental rigor by methodologists. An ASCO Endorsement Panel subsequently reviewed the content and the recommendations.RESULTS The ASCO Endorsement Panel determined that the recommendations from the CAP guideline, published on August 3, 2022, are clear, thorough, and based on the most relevant scientific evidence. ASCO endorses Mismatch Repair and Microsatellite Instability Testing for Immune Checkpoint Inhibitor Therapy: Guideline From the College of American Pathologists in Collaboration With the Association for Molecular Pathology and Fight Colorectal Cancer.RECOMMENDATIONS Within the guideline, MMR immunohistochemistry (IHC), MSI polymerase chain reaction, and MSI next-generation sequencing are all recommended testing options for colorectal cancer, MMR-IHC and MSI-polymerase chain reaction for gastroesophageal and small bowel cancer, and only MMR-IHC for endometrial cancer. No recommendation in favor of any testing method over another could be made for any other cancer. Tumor mutational burden was not recommended as a surrogate for DNA MMR deficiency. If MMR deficiency consistent with Lynch syndrome is detected, it should be communicated to the treating physician.
  • conferenceObject
    Causes of unplanned hospitalizations and factors associated with in-hospital mortality among patients receiving chemotherapy treatment
    (2022) HIDALGO FILHO, C. M. T.; LAZAR NETO, F.; ROCHA, J. W. D.; SOBOTTKA, V. P.; STANGLER, L. T. B.; BENFATTI, G.; GUEDES, H.; CLARO, M. Z.; BONADIO, R. C.; DIZ, M. D. P. E.; HOFF, P. M.